NCT05321979View on ClinicalTrials.gov

Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

PHASE3CompletedINTERVENTIONAL

Enrollment

253

Participants

Timeline

Start Date

February 7, 2022

Primary Completion Date

May 30, 2023

Study Completion Date

May 30, 2023

Conditions

Glabellar Frown Lines

Interventions

DRUG

MBA-P01

MBA-P01 will be injected into the Glabellar line.

Trial Locations (1)

06973

Chung-Ang Univ. Hospital, Seoul

All Listed Sponsors

lead

Medytox Korea

INDUSTRY